| Cash, cash equivalents, and marketable securities |
Note
4 - Cash, cash equivalents, and marketable securities
The following table provides a
reconciliation of cash, cash equivalents, and restricted cash reported within our unaudited condensed consolidated balance sheets as of
March 31, 2026 and March 31, 2025, to the total of such amounts as presented in the unaudited condensed consolidated statements of cash
flows (in thousands):
| Schedule reconciliation of cash, cash equivalents, and restricted cash | |
| | |
| |
|
|
| | |
March 31, 2026 | |
| March 31, 2025 |
|
| Cash and cash equivalents | |
$ | 6,558 | |
| $ |
8,899 |
|
| Restricted cash, noncurrent | |
| 2,604 | |
| |
2,604 |
|
| Total cash, cash equivalents, and restricted cash | |
$ | 9,162 | |
| $ |
11,503 |
|
Cash,
cash equivalents, and marketable securities consisted of the following as of March 31, 2026 and December 31, 2025 (in thousands):
| Schedule of cash and cash equivalents | |
| | | |
| | |
| | |
March 31, 2026 | | |
December 31, 2025 | |
| Cash and cash equivalents: | |
| | | |
| | |
| Cash | |
$ | 3,251 | | |
$ | 1,386 | |
| Money market funds | |
| 3,307 | | |
| 4,408 | |
| Total cash and cash equivalents | |
$ | 6,558 | | |
$ | 5,794 | |
| Marketable securities, short-term: | |
| | | |
| | |
| Asset backed securities | |
$ | 1,008 | | |
$ | 1,012 | |
| Commercial paper | |
| 1,783 | | |
| 9,125 | |
| Corporate bonds | |
| 12,672 | | |
| 18,171 | |
| US Treasury securities | |
| 7,852 | | |
| 19,087 | |
| Total marketable securities, short-term | |
$ | 23,315 | | |
$ | 47,395 | |
| Marketable securities, long-term: | |
| | | |
| | |
| Asset backed securities | |
$ | 1,006 | | |
$ | 1,011 | |
| Total marketable securities, long-term | |
$ | 1,006 | | |
$ | 1,011 | |
| Total cash, cash equivalents, and marketable securities | |
$ | 30,879 | | |
$ | 54,200 | |
During the three-month period
ended March 31, 2026 and 2025, marketable securities were sold or matured for proceeds of $24.2 million and $18.0 million, respectively.
The Company recorded an immaterial amount of realized gain during the for the three months ended March 31, 2026 and 2025. See Note 5,
“Fair value measurements” for additional information regarding the fair value of cash equivalents and marketable securities.
The following tables summarizes
the unrealized gains and losses related to the Company’s available-for-sale marketable securities, by major security type, as of
March 31, 2026 and December 31, 2025 (in thousands):
| Schedule of unrealized gains and losses | |
| | | |
| | | |
| | | |
| | |
| | |
As of March 31, 2026 | |
| | |
Amortized | | |
Unrealized | | |
Unrealized | | |
| |
| | |
Cost | | |
Gains | | |
(losses) | | |
Fair Value | |
| Marketable securities | |
| | | |
| | | |
| | | |
| | |
| Asset backed securities | |
$ | 2,015 | | |
$ | - | | |
$ | (1 | ) | |
$ | 2,014 | |
| Commercial paper | |
| 1,783 | | |
| - | | |
| - | | |
| 1,783 | |
| Corporate bonds | |
| 12,670 | | |
| 3 | | |
| (1 | ) | |
| 12,672 | |
| US Treasury securities | |
| 7,848 | | |
| 4 | | |
| - | | |
| 7,852 | |
| Total marketable securities | |
$ | 24,316 | | |
$ | 7 | | |
$ | (2 | ) | |
$ | 24,321 | |
| | |
As of December 31, 2025 | |
| | |
Amortized | | |
Unrealized | | |
Unrealized | | |
| |
| | |
Cost | | |
Gains | | |
(losses) | | |
Fair Value | |
| Marketable securities | |
| | | |
| | | |
| | | |
| | |
| Asset backed securities | |
$ | 2,022 | | |
$ | 1 | | |
$ | - | | |
$ | 2,023 | |
| Commercial paper | |
| 9,120 | | |
| 5 | | |
| - | | |
| 9,125 | |
| Corporate bonds | |
| 18,148 | | |
| 23 | | |
| - | | |
| 18,171 | |
| US Treasury securities | |
| 19,062 | | |
| 25 | | |
| - | | |
| 19,087 | |
| Total marketable securities | |
$ | 48,352 | | |
$ | 54 | | |
$ | - | | |
$ | 48,406 | |
The following
table shows the unrealized losses and fair values for those marketable securities that were in an unrealized loss position as of March
31, 2026 and December 31, 2025, aggregated by major security type and the length of time the marketable securities have been in a continuous
loss position (in thousands):
| Schedule of marketable securities | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| | |
As of March 31, 2026 | |
| | |
In Loss Position for Less Than 12 Months | | |
In Loss Position for 12 Months or Greater | | |
Total | |
| | |
Fair Value | | |
Unrealized Losses | | |
Fair Value | | |
Unrealized Losses | | |
Fair Value | | |
Unrealized Losses | |
| Asset backed securities | |
$ | 2,014 | | |
$ | (1 | ) | |
$ | - | | |
$ | - | | |
$ | 2,014 | | |
$ | (1 | ) |
| Commercial paper | |
| 1,190 | | |
| - | | |
| - | | |
| - | | |
| 1,190 | | |
| - | |
| Corporate bonds | |
| 4,572 | | |
| (1 | ) | |
| - | | |
| - | | |
| 4,572 | | |
| (1 | ) |
| US Treasury Securities | |
| 352 | | |
| - | | |
| - | | |
| - | | |
| 352 | | |
| - | |
| Total | |
$ | 8,128 | | |
$ | (2 | ) | |
$ | - | | |
$ | - | | |
$ | 8,128 | | |
$ | (2 | ) |
| | |
As of December 31, 2025 | |
| | |
In Loss Position for Less Than 12 Months | | |
In Loss Position for 12 Months or Greater | | |
Total | |
| | |
Fair Value | | |
Unrealized Losses | | |
Fair Value | | |
Unrealized Losses | | |
Fair Value | | |
Unrealized Losses | |
| Commercial paper | |
$ | 1,000 | | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | 1,000 | | |
$ | - | |
| Corporate Bonds | |
| 298 | | |
| - | | |
| - | | |
| - | | |
| 298 | | |
| - | |
| Total | |
$ | 1,298 | | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | 1,298 | | |
$ | - | |
The contractual
maturities of the Company’s marketable securities as of March 31, 2026, were as follows (in thousands):
| Schedule of contractual maturities | |
| | |
| | |
Fair Value | |
| One year or less | |
$ | 23,315 | |
| Two years to three years | |
| 1,006 | |
| Total minimum payments | |
$ | 24,321 | |
|